KERYX BIOPHARMACEUTICALS INC: change in accounts receivable

What this measure means

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Exact concept: us-gaap:IncreaseDecreaseInAccountsReceivable. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2014-01-01 to 2017-12-31. The SEC response was captured on 2026-09-22.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related KERYX BIOPHARMACEUTICALS INC histories

• Total assets
• Total liabilities
• Stockholders equity
• Cash and cash equivalents
• Net income or loss
• Operating cash flow
• Capital expenditure payments
• Revenue
• Financing cash flow
• Investing cash flow
• Retained earnings or deficit
• Basic weighted-average shares
• Diluted weighted-average shares
• Basic earnings per share
• Diluted earnings per share
• Income tax expense or benefit
• Net property, plant and equipment
• Share-based compensation expense
• Operating income or loss
• Current assets
• Interest expense
• Current liabilities
• Current accounts payable
• Goodwill carrying amount
• Net current accounts receivable
• Operating expenses
• Net inventory
• Selling, general and administrative expense
• Research and development expense
• Common shares outstanding
• Gross property, plant and equipment
• Accumulated depreciation on property, plant and equipment
• Other noncurrent assets
• Other noncurrent liabilities
• Net deferred tax liabilities
• Comprehensive income or loss
• General and administrative expense
• Depreciation expense
• Depreciation, depletion and amortization
• Other nonoperating income or expense
• Nonoperating income or expense
• Deferred income tax expense or benefit
• Proceeds from issuing common stock
• Change in inventories

Inspect the source

Entity

KERYX BIOPHARMACEUTICALS INC / CIK 0001114220

Captured

2026-09-22 19:41 UTC

SEC response SHA-256

7185e222dc2993abdd2db1f8a304a0548c5ebb488c75064e4ec3caabea49020d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001114220.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))